At DCVC Bio, we see a need for a massive reinvestment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies. More on our thinking 👇 https://lnkd.in/g2eQffuH
DCVC Bio Seeks New Anxiety Treatments
This title was summarized by AI from the post below.
More Relevant Posts
-
The biopharma sector is at an inflection point, and 2026 could be a defining year. Biotech momentum is returning. Capital markets are reopening. M&A activity is accelerating. We break down the 4 key questions shaping biopharma right now—and what they mean for investors, operators, and patients. Which will have the biggest impact in 2026? #BioPharma #LifeSciences #Biotech #HealthcareInnovation #FDA #MedicalAffairs #DrugDevelopment
-
The biopharma sector is at an inflection point, and 2026 could be a defining year. Biotech momentum is returning. Capital markets are reopening. M&A activity is accelerating. We break down the 4 key questions shaping biopharma right now—and what they mean for investors, operators, and patients. Which will have the biggest impact in 2026? #BioPharma #LifeSciences #Biotech #HealthcareInnovation #FDA #MedicalAffairs #DrugDevelopment
-
2026 could be a turning point for biopharma. Biotech momentum is rising again, capital markets are reopening, and M&A is picking up. We explored the four biggest questions shaping the industry right now. Which one will matter most in 2026? Share your perspective. #BioPharma #LifeSciences #Biotech #HealthcareInnovation #FDA #MedicalAffairs #DrugDevelopment
-
2026 could be a turning point for biopharma. Biotech momentum is rising again, capital markets are reopening, and M&A is picking up. We explored the four biggest questions shaping the industry right now. Which one will matter most in 2026? Share your perspective. #BioPharma #LifeSciences #Biotech #HealthcareInnovation #FDA #MedicalAffairs #DrugDevelopment
-
2026 could be a turning point for biopharma. Biotech momentum is rising again, capital markets are reopening, and M&A is picking up. We explored the four biggest questions shaping the industry right now. Which one will matter most in 2026? Share your perspective. #BioPharma #LifeSciences #Biotech #HealthcareInnovation #FDA #MedicalAffairs #DrugDevelopment
-
Bristol-Myers Squibb wrote this company a $3.6 billion check. The drug failed. The stock crashed 99%. Then it ripped over 1,000%. #NKTR #NektarTherapeutics #Biotech #StockMarket #Investing
-
Biotech isn’t growing. It’s rolling its debt. Biotech Fragility Series: Funding Lens Amgen 46 Gilead 49 Regeneron 55 Biogen 67 Moderna 76 Markets detect fragility after the regime changes. The Tsakas Fragility Radar detects it in advance. The market is pricing this as growth. It isn’t. Cheap capital makes this look stable. If capital tightens… what actually survives? Defend your allocation. #FragilityRadar #Biotech #Healthcare #Investing #Pharma
-
-
One thing I’ve learned over time: partnerships matter most when they help teams make better decisions earlier. Early integration across development, manufacturing, and partners helps surface risks sooner and enables faster, more effective solutions across the development lifecycle. Thank you to BioPharm International for the opportunity to be part of the first episode of their new video series and for a thoughtful discussion on how partnership models continue to evolve in bioprocessing and biopharma development. #BMS_Employee
BioPharm International is proud to present the debut of the BioPharm Drug Digest video series! As modalities grow more complex, no single organization can sustain all required capabilities in-house. Companies increasingly depend on specialized partners, contract development manufacturing organizations, and technology providers. Join the discussion with Bristol Myers Squibb's Dr. Manisha Desai as we examine the impact of evolving partnership models on bioprocessing and biopharma R&D in the debut episode: https://hubs.li/Q048FJWc0 #BiopharmaPartnerships #BioprocessingInnovation #CDMOCollaboration #DrugDevelopment #BioPharmDrugDigest
-
-
BioPharm International is proud to present the debut of the BioPharm Drug Digest video series! As modalities grow more complex, no single organization can sustain all required capabilities in-house. Companies increasingly depend on specialized partners, contract development manufacturing organizations, and technology providers. Join the discussion with Bristol Myers Squibb's Dr. Manisha Desai as we examine the impact of evolving partnership models on bioprocessing and biopharma R&D in the debut episode: https://hubs.li/Q048FJWc0 #BiopharmaPartnerships #BioprocessingInnovation #CDMOCollaboration #DrugDevelopment #BioPharmDrugDigest
-
-
Biopharma companies are reshaping R&D and market strategies to improve efficiency and stay competitive in a rapidly evolving industry. Read more: https://lnkd.in/dVheRepm #Pharma #Biotech #DrugDevelopment #Healthcare
-
